These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 53370)

  • 1. Effect of group-A meningococcal vaccine in army recruits in Finland.
    Mäkelä PH; Käyhty H; Weckström P; Sivonen A; Renkonen OV
    Lancet; 1975 Nov; 2(7941):883-6. PubMed ID: 53370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine.
    Masterton RG; Youngs ER; Wardle JC; Croft KF; Jones DM
    J Infect; 1988 Sep; 17(2):177-82. PubMed ID: 3141518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates.
    Sivonen A
    J Infect; 1981 Sep; 3(3):266-72. PubMed ID: 6821094
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of epidemic meningococcal meningitis by mass vaccination.
    Mohammed I; Zaruba K
    Lancet; 1981 Jul; 2(8237):80-2. PubMed ID: 6113451
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.
    Mohammed I; Obineche EN; Onyemelukwe GC; Zaruba K
    J Infect; 1984 Sep; 9(2):190-6. PubMed ID: 6438244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
    Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
    Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
    Pearce MC; Sheridan JW; Jones DM; Lawrence GW; Murphy DM; Masutti B; McCosker C; Douglas V; George D; O'Keefe A
    Lancet; 1995 Jul; 346(8966):20-3. PubMed ID: 7603139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy.
    Binkin N; Band J
    Lancet; 1982 Aug; 2(8293):315-8. PubMed ID: 6124726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.
    Sanborn WR; Bencić Z; Cvjetanović B; Gotschlich EC; Pollock TM; Sippel JE
    Prog Immunobiol Stand; 1971; 5():497-505. PubMed ID: 4633977
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of meningococcal infection in the African meningitis belt by selective vaccination.
    Greenwood BM; Wali SS
    Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal carriage, meningococcal disease and vaccination.
    Hassan-King MK; Wall RA; Greenwood BM
    J Infect; 1988 Jan; 16(1):55-9. PubMed ID: 3130424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
    Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
    Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemic meningococcal meningitis in central Australia, 1987-1991.
    Patel MS; Merianos A; Hanna JN; Vartto K; Tait P; Morey F; Jayathissa S
    Med J Aust; 1993 Mar; 158(5):336-40. PubMed ID: 7605395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state.
    Gotschlich EC; Goldschneider I; Artenstein MS
    J Exp Med; 1969 Jun; 129(6):1385-95. PubMed ID: 4977284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group-specific meningococcal vaccination and epidemics caused by other groups of meningococci.
    Mäkelä PH; Peltola H
    Lancet; 1978 Oct; 2(8093):780-1. PubMed ID: 80699
    [No Abstract]   [Full Text] [Related]  

  • 19. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
    Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM
    Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
    Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
    Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.